Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Furosemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | CA6 | P23280 | 2/20 | 1.00 |
| ▸ | CA5A | P35218 | 2/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | HSD11B1 | P28845 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 9/20 | 0.77 |
| ▸ | TEX264 | Q9Y6I9 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Furosemide SCHEMBL9811 | 1.00 | CISD1 (1.00) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL428921 | 1.00 | CISD1 (1.00) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL11319593 | 0.99 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL10867860 | 0.99 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL8092440 | 0.99 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL10339959 | 0.99 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL2953945 | 0.99 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL1109955 | 0.99 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL2519788 | 0.99 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL6751172 | 0.99 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113271923-B | Pharmaceutical composition of furosemide and application thereof | SQ创新股份公司 | 2025-05-13 | — | — | CN | claimed |
| US-20250043174-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE COMPRISING SAME | BEIJING SUMMER SPROUT TECHNOLOGY CO., LTD (CN) | 2025-02-06 | — | — | US | claimed |
| US-20240368465-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE COMPRISING SAME | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-11-07 | — | — | US | claimed |
| US-11903305-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-13 | — | — | US | claimed |
| US-11711969-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-25 | — | — | US | claimed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | claimed |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | disclosed |
| CN-114401960-B | Glue degradation agent and using method thereof | NOVARTIS AG (CH) | 2026-05-26 | — | — | CN | disclosed |
| US-20260137673-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115148-A1 | HOMEOPATHIC THERAPEUTIC METHOD AND COMPOSITIONS | CEARNA INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| US-20220072131-A1 | Dihydroxyphenyl Neurotransmitter Compounds, Compositions And Methods | AUSPEX PHARMACEUTICALS INC (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
| US-11260127-B2 | Mesoporous silica nanoparticles for diagnostic and therapeutic applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
| US-11260058-B2 | Compositions and method of treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-01 | — | — | US | disclosed |
| CN-114010632-A | Enalapril maleate and furosemide compound tablet and preparation method and application thereof | 上海汉维生物医药科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | DRD2, HTR2C, SLC18A2 | CISD1 1076/4885ALDH1A1 2019/4885CA12 4147/4885 |
| US-11711969-B2 | Organic electroluminescent materials and devices | RPS4X, NCOA4, KCNN4 | CISD1 4072/4885ALDH1A1 3044/4885CA12 1208/4885 |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | CISD1 1663/4885ALDH1A1 4001/4885CA12 655/4885 |
| US-20220072131-A1 | Dihydroxyphenyl Neurotransmitter Compounds, Compositions And Methods | SLC18A2, COMT, SLC6A2 | CISD1 4250/4885ALDH1A1 1234/4885CA12 2298/4885 |
| US-20220071935-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CISD1 3650/4885ALDH1A1 835/4885CA12 1338/4885 |
| US-11260058-B2 | Compositions and method of treating cancer | TP53, HCCS, TOP2A | CISD1 4067/4885ALDH1A1 2183/4885CA12 104/4885 |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | HTR1D, HTR5A, PCNP | CISD1 1194/4885ALDH1A1 1593/4885CA12 4532/4885 |
| US-11903305-B2 | Organic electroluminescent materials and devices | OGFRL1, OPRM1, OSBP | CISD1 459/4885ALDH1A1 801/4885CA12 3157/4885 |
| US-20260115148-A1 | HOMEOPATHIC THERAPEUTIC METHOD AND COMPOSITIONS | HIRA, GJA1, CD44 | CISD1 2500/4885ALDH1A1 1050/4885CA12 778/4885 |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | FLNB, SETD1B, HTR5A | CISD1 1598/4885ALDH1A1 2033/4885CA12 3489/4885 |
| US-20260137673-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | HTT, HTR2C, NSD1 | CISD1 651/4885ALDH1A1 2310/4885CA12 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.